Pharmafile Logo
Pharmafocus logo
Advanced Search

Sales and Marketing

Showing 15 posts of 11528 posts found.

NHS sign

NICE rejects BMS cancer drug in draft guidance

December 16, 2015 Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, NHS, NICE, lung cancer, nivolumab, non small cell lung cancer, non-small cell lung cancer, opdivo

In draft guidance, NICE has chosen not to recommend Bristol-Myers Squibb’s Opdivo for the treatment of locally advanced or metastatic …
News
Kadcyla

NICE says no to NHS funding for Kadcyla

December 16, 2015 Research and Development, Sales and Marketing Breast Cancer Now, Kadcyla, NHS, NICE, Roche, advanced breast cancer, breast cancer

NICE has turned down Roche’s application for NHS funding for Kadcyla as a treatment for a type of advanced breast …
News
amgen_hq

Amgen buys back rights to three drugs from GSK

December 15, 2015 Research and Development, Sales and Marketing Amgen, GSK

Amgen has announced that it will reacquire the rights to three products in 48 countries from GSK, as it seeks …
News
Sanofi BI logos

Pharma giants Sanofi and Boehringer negotiate deal to swap assets

December 15, 2015 Business Services, Manufacturing and Production, Sales and Marketing Andreas Barner, Boehringer, Boehringer Ingelheim, Merial, Sanofi, olivier brandicourt

Two of the world’s biggest pharma companies – Sanofi and Boehringer Ingelheim – have entered into exclusive negotiations to swap …
News
personal-95715_640

Mirror. Signal. Merger. How to deal with a pharma takeover

December 14, 2015 Manufacturing and Production, Medical Communications, Sales and Marketing Deals, acquisition, buyouts, mergers, takeovers

So 2015 has been a record year for M&A in the pharma industry.The Financial Times has called this “the most …
Feature
AZ building

AstraZeneca in $5bn Acerta buyout talks

December 14, 2015 Sales and Marketing Acerta Pharma, AstraZeneca, acalabrutinib, acquisitions, blood cancer, buyout, chronic lymphocytic leukaemia, mergers, takeover

AstraZeneca has confirmed it is in negotiations to buy cancer drug developer Acerta Pharma BV for more than $5 billion …
News
Chest x ray

Roche lung cancer drug Alecensa gets rapid US approval

December 14, 2015 Sales and Marketing Alecensa, FDA, Genentech, Roche, accelerated approval, alectinib, lung cancer, non-small cell lung cancer

The US health watchdog has approved Alecensa, a drug for people with certain types of non-small cell lung cancer manufactured …
News
Novartis image

Novartis earns provisional NICE yes for Entresto

December 11, 2015 Sales and Marketing Entresto, NICE, Novartis, chronic heart failure, heart failure

NICE has indicated it is likely to recommend Entresto, a novel drug manufactured by Novartis, as a treatment option for …
News
labcorps_purchase_of_covance_topped_the_outsourcing_deals_in_2015

M&A activity drives record year for pharma outsourcing deals

December 11, 2015 Sales and Marketing Covance, M&A, MA, labcorp, outsourcing

A drastic increase pharma industry in M&A activity has propelled the value of pharmaceutical outsourcing deals from $9.9 billion in …
News
halaven

Eisai’s Halaven shown to restrict further cancer metastasis

December 11, 2015 Research and Development, Sales and Marketing Eisai, Halaven, Merck, keytruda

New data presented by Eisai supports the previously shown ability of Halaven (eribulin) to reverse epithelial-to-mesenchymal transition, the process by …
News
Lynparza

NICE recommends AstraZeneca’s Lynparza after price reduction

December 11, 2015 Medical Communications, Sales and Marketing AstraZeneca, NICE, fallopian tube cancer, lynparza, olaparib, ovarian cancer, peritoneal cancer

NICE has recommended AstraZeneca’s Lynparza for maintenance treatment of relapsed ovarian, fallopian tube and peritoneal cancer. In draft guidance the …
News

NICE publishes draft guidance on two prostate cancer treatments

December 11, 2015 Medical Communications, Research and Development, Sales and Marketing Astellas, Janssen, NICE, Xtandi, Zytiga, prostate cancer

NICE has issued final draft guidance recommending Astellas Pharma’s Xtandi (enzalutamide) in prostate cancer prior to chemotherapy, but not Janssen’s …
News
Novolog pen

Novo Nordisk files for new insulin approval

December 10, 2015 Manufacturing and Production, Research and Development, Sales and Marketing FDA, NDA, Novo Nordisk, NovoLog, diabetes, insulin aspart, new drug application

Novo Nordisk has submitted a New Drug Application (NDA) for faster-acting insulin aspart to the FDA. If successful, the Danish …
News
cindy_whitehead

‘Female Viagra’ CEO leaves company

December 10, 2015 Medical Communications, Sales and Marketing Addyi, Cindy Whitehead, Sprout Pharma

Cindy Whitehead has left Sprout Pharmaceuticals, just four months after guiding the female libido drug Addyi to FDA approval and overseeing …
Appointment
Janssen image

Janssen submits Stelara for EU approval for Crohn’s

December 9, 2015 Sales and Marketing Crohn’s disease, EMA, European Medicines Agency, Janssen, Stelara, crohn's disease, ustekinumab

Janssen today announced that it has submitted an application to the European Medicines Agency, seeking approval of Stelara in Crohn’s …
News
The Gateway to Local Adoption Series

Latest content

Cori Clinical raises US$4m to expand AI platform for clinical trial design

October 14, 2026

Ofichem acquires US drug substance CDMO Kinentia

October 14, 2026

Jager-van Dijk is new Arletta Pharma Solutions CEO 

October 13, 2026

Tridem begins phase Ib trial of Parkinson’s disease vaccine

October 13, 2026

Bio-Techne opens GMP small-molecule manufacturing facility in Bristol

October 13, 2026